An Open Label, Multicenter Phase I/II Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Relapsed and/or Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs P 276 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker
- Sponsors Piramal Life Sciences
- 28 Sep 2012 Status changed from recruiting to completed as reported by Clinical Trials Registry - India.
- 09 Jun 2011 Planned End Date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 22 Jul 2009 New source identified and integrated (Clinical Trials Registry - India, CTRI2008-091-000004).